Get the Stockscreener App
0.7864
6.16%
-0.0516
After Hours:
.81
0.0236
+3.00%
Evogene Ltd stock is traded at $0.7864, with a volume of 247.76K.
It is down -6.16% in the last 24 hours and down -28.51% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$0.838
Open:
$0.829
24h Volume:
247.76K
Relative Volume:
0.61
Market Cap:
$6.86M
Revenue:
$6.74M
Net Income/Loss:
$-14.74M
P/E Ratio:
-0.3497
EPS:
-2.2491
Net Cash Flow:
$-18.31M
1W Performance:
-8.63%
1M Performance:
-28.51%
6M Performance:
-34.63%
1Y Performance:
-44.37%
1-Day Range:
$0.73
$0.8359
1-Week Range:
$0.73
$0.8845
52-Week Range:
$0.73
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.7864 | 7.31M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains By Investing.com - Investing.com India
Evogene: Q4 Earnings Snapshot - KVUE
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com India
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks
EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative
Evogene Earnings Review: Q4 Summary - Benzinga
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
An Overview of Evogene's Earnings - Benzinga
Evogene Ltd expected to post a loss of 26 cents a shareEarnings Preview - TradingView
EVGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EVGN Should I Buy - Intellectia AI
Is Evogene Ltd. stock heavily shortedJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Evogene refocuses on AI drug discovery platform ChemPass By Investing.com - Investing.com India
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - The Globe and Mail
Evogene refocuses on AI drug discovery platform ChemPass - Investing.com
Evogene Releases CEO Letter to Shareholders - Finviz
Evogene substantially completed divestment of non-core subsidiaries - marketscreener.com
Evogene (EVGN) pivots to ChemPass AI and core health and ag markets - Stock Titan
Fund Flows: Does Evogene Ltd have consistent dividend growth2025 Market WrapUp & AI Based Trade Execution Alerts - baoquankhu1.vn
Winners Losers: Is ProShares Trust ProShares UltraShort Consumer Staples likely to announce a buybackWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CEO Moves: Is Evogene Ltd in a consolidation phaseJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release – Company Announcement - Financial Times
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release - Barchart.com
Evogene and QUT partner on AI-based cancer therapies - Pharmaceutical Business review -
Ideas Watch: Is Huntington Ingalls Industries Inc a good stock for dollar cost averaging2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - StreetInsider
Will Evogene Ltd. stock hit new highs in YEARBear Alert & Accurate Entry/Exit Alerts - mfd.ru
Why did EVGN shares drop more than 14% today? - MSN
What insider trading reveals about Evogene Ltd. stockMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Will Evogene Ltd. stock benefit from AI adoptionJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru
Evogene Ltd. Expands Google Cloud Collaboration to Integrate AI Agents into ChemPass AI™ - iGrow News
Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Finviz
Evogene expands Google Cloud collaboration to enhance AI platform - Investing.com Australia
Evogene announces warrant inducement deal for $3.4 million By Investing.com - Investing.com Australia
Evogene expands Google Cloud collaboration to enhance AI platform By Investing.com - Investing.com Canada
Evogene stock rises as company expands Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene stock rises as company expands Google Cloud collaboration - Investing.com
Evogene announces warrant inducement deal for $3.4 million - Investing.com Nigeria
Evogene Enters Warrant Inducement Agreement Amid Stock Decline - Intellectia AI
Why Did EVGN Shares Drop More Than 14% Today? - Asianet Newsable
Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):